The era of personalized cancer care has dawned, and a number of disease subsets have validated targets coupled with therapeutic agents delivering meaningful clinical benefit. As we tiptoe into molecularly targeted oncology, few would have predicted that lung cancer would be the disease leading the way to individualized therapy. Half a decade ago, we were stuck with the awkward designation of lung cancer into small-cell type and non–small cell type, the latter including a variety of histologically...